Tag

Tag: Georgia Product Liability Law

  • Georgia Product Liability Law

    Defective Medical Device Cases in Georgia

    <p>The FDA pathway controls almost everything. Medical device product liability sits at the intersection of Georgia state law, federal FDA regulation, and the learned intermediary doctrine. The viability of claims depends substantially on how the device was approved by the FDA, what theories are pleaded, and whether federal preemption under <em>Riegel v. Medtronic</em> applies.</p> <table> <thead> <tr> <th>FDA approval pathway</th> <th>Review intensity</th> <th><em>Riegel</em> preemption</th> <th>Available state law claims</th> </tr> </thead> <tbody> <tr> <td>Premarket Approval (PMA)</td> <td>Most rigorous; Class III high-risk devices</td> <td>Yes; bars claims imposing duties beyond FDA requirements</td> <td>Parallel claims only (state duty must match federal requirement)</td> </tr> <tr> <td>510(k) clearance</td> <td>Substantial-equivalence review to predicate devices</td> <td>Generally no preemption</td> <td>Standard design defect, manufacturing defect, failure to warn</td> </tr> <tr> <td>De Novo classification</td> <td>Novel devices without predicate; intermediate review</td> <td>Analysis is fact-specific</td> <td>Variable; depends on FDA conditions imposed</td> </tr> </tbody> </table> <h2>The FDA approval pathway determines preemption exposure</h2> <p>Medical devices reach the U.S. market through three primary FDA pathways:</p> <ul> <li><strong>Premarket Approval (PMA):</strong> The most rigorous pathway for Class III high-risk devices. Devices that received PMA are subject to federal preemption under <em>Riegel v. Medtronic, Inc.</em>, 552 U.S. 312 (2008).</li> <li><strong>510(k) clearance:</strong> Devices substantially equivalent to existing devices receive 510(k) clearance through a less rigorous review. Devices cleared through 510(k) are generally not subject to <em>Riegel</em> preemption.</li> <li><strong>De Novo classification:</strong> A pathway for novel devices that do not have predicate devices. Preemption analysis is more complex.</li> </ul> <p>The preemption analysis is therefore not uniform across medical devices. A plaintiff’s first task is identifying the FDA approval pathway for the specific device.</p> <h2>PMA-approved devices face strong preemption defenses</h2> <p>For PMA-approved devices, <em>Riegel</em> preemption blocks state law claims that would impose duties different from or in addition to federal requirements. This effectively bars:</p> <ul> <li>State law claims seeking to require warnings beyond FDA-approved labeling</li> <li>State law claims alleging design defects in features specifically approved by the FDA</li> <li>State law claims based on manufacturing methods specifically approved by the FDA</li> </ul> <p>What remains available are “parallel claims” (state law claims based on the manufacturer’s failure to comply with the FDA-approved specifications). A plaintiff alleging that the device was manufactured in violation of the FDA-approved manufacturing process can proceed, because the </p>

    5 min read
  • Georgia Product Liability Law

    Filing a Product Liability Lawsuit in Georgia: Procedural Steps

    <p>A Georgia product liability lawsuit involves procedural steps beyond the standard personal injury case. Pre-suit investigation of the product, evidence preservation, identification of multiple potential defendants, and analysis of federal preemption questions all precede the filing. The complaint follows preparatory work that shapes which theories can be pleaded and which defendants can be named.</p> <table> <thead> <tr> <th>Deadline</th> <th>Trigger</th> <th>Length</th> <th>Source</th> </tr> </thead> <tbody> <tr> <td>Statute of limitations</td> <td>Date of injury</td> <td>2 years (personal injury)</td> <td>O.C.G.A. § 9-3-33</td> </tr> <tr> <td>Statute of limitations</td> <td>Date of injury</td> <td>2 years (wrongful death)</td> <td>O.C.G.A. § 9-3-33</td> </tr> <tr> <td>Statute of repose (strict liability)</td> <td>First sale of product to intended consumer</td> <td>10 years</td> <td>O.C.G.A. § 51-1-11(b)(2)</td> </tr> <tr> <td>Statute of repose (negligence)</td> <td>First sale (with § 51-1-11(c) exceptions)</td> <td>10 years</td> <td>O.C.G.A. § 51-1-11(c)</td> </tr> <tr> <td>Ante litem notice (state defendant)</td> <td>Date of injury</td> <td>12 months (state); 6 months (municipal)</td> <td>O.C.G.A. § 50-21-26; § 36-33-5</td> </tr> <tr> <td>Workers' comp lien notice</td> <td>Filing of third-party suit</td> <td>Per workers' comp procedure</td> <td>Georgia workers' compensation law</td> </tr> </tbody> </table> <h2>Step 1: Preserve the product and related evidence</h2> <p>Product preservation is the threshold issue in any product liability case. Without the product itself, design defect and manufacturing defect claims become exceedingly difficult to prove. Early steps in a product liability case typically include:</p> <ul> <li>Securing the injuring product</li> <li>Preserving all packaging, instructions, warnings, and accompanying materials</li> <li>Identifying and preserving any related components, parts, or accessories</li> <li>Documenting the product’s condition with photographs and video</li> <li>Preserving any maintenance records, service histories, or modification records</li> </ul> <p>Spoliation letters to known parties (the plaintiff’s employer in workplace cases, the dealer or seller, any insurance carrier with possession, towing or salvage facilities) typically go out immediately to prevent destruction of evidence.</p> <h2>Step 2: Identify the FDA approval pathway (medical device and pharmaceutical cases)</h2> <p>For medical devices and pharmaceuticals, identifying the regulatory pathway is essential before filing because of federal preemption implications:</p> <ul> <li><strong>Medical devices:</strong> Determine whether the device received Premarket Approval (PMA) or 510(k) clearance. PMA devices face <em>Riegel</em> preemption; 510(k) devices generally do not.</li> <li><strong>Brand-name vs. generic drugs:</strong> Determine whether the plaintiff took the brand-name drug (failure-to-warn claims generally available under <em>Wyeth</em>) or a generic version (failure-to-warn claims preempted under <em>PLIVA</em>).</li> </ul> <p>This analysis affects </p>

    6 min read
  • Georgia Product Liability Law

    Industrial Equipment and Workplace Product Liability

    <p>When a worker is injured by defective industrial equipment in Georgia, two systems run alongside each other: workers’ compensation against the employer and third-party product liability against the equipment manufacturer. The structural separation allows recovery from both sources but creates lien obligations and apportionment complexity that affect what the injured worker ultimately receives.</p> <table> <thead> <tr> <th></th> <th>Workers' compensation</th> <th>Third-party product liability</th> </tr> </thead> <tbody> <tr> <td>Defendant</td> <td>Employer (or statutory employer under § 34-9-8)</td> <td>Equipment manufacturer (and component manufacturers)</td> </tr> <tr> <td>Theory</td> <td>No-fault, exclusive remedy</td> <td>Strict liability under § 51-1-11; negligence</td> </tr> <tr> <td>Available benefits</td> <td>Medical, indemnity, death benefits to dependents</td> <td>Full tort damages (compensatory + punitive)</td> </tr> <tr> <td>Plaintiff's fault</td> <td>Not a bar</td> <td>Comparative negligence under § 51-12-33</td> </tr> <tr> <td>Employer fault</td> <td>N/A (immunity)</td> <td>Apportioned as non-party under § 51-12-33 (reduces recovery)</td> </tr> <tr> <td>Carrier lien</td> <td>N/A</td> <td>Workers' compensation carrier holds lien on third-party recovery</td> </tr> </tbody> </table> <h2>Workers’ compensation against the employer; product liability against the manufacturer</h2> <p>Under Georgia’s workers’ compensation law, an employee injured on the job has workers’ compensation as the exclusive remedy against the employer. The exclusive remedy bars wrongful death and personal injury claims against the employer for workplace injuries, providing no-fault benefits regardless of who was at fault.</p> <p>But the exclusive remedy doctrine does not bar claims against third parties, including the manufacturer of defective equipment that caused the injury. When industrial equipment is the source of injury, the worker has:</p> <ul> <li>Workers’ compensation benefits from the employer (medical, indemnity, in fatal cases death benefits to dependents)</li> <li>Third-party product liability claim against the equipment manufacturer under O.C.G.A. § 51-1-11</li> </ul> <p>The third-party claim is separate from the workers’ compensation claim and proceeds in tort under the standard product liability framework.</p> <h2>Industrial equipment cases fall into recurring defect categories</h2> <p>Industrial equipment product liability cases in Georgia regularly involve:</p> <ul> <li><strong>Machinery without adequate guards:</strong> Equipment designed without point-of-operation guards, presence-sensing devices, or other safety features</li> <li><strong>Defective safety controls:</strong> Emergency stops, two-hand controls, or interlock systems that did not work as intended</li> <li><strong>Inadequate warnings on industrial equipment:</strong> Warnings that did not address actual operational hazards</li> <li><strong>Lockout-tagout failures:</strong> Equipment designs that did not adequately support energy isolation</li> <li><strong>Heavy equipment defects:</strong> Cranes, forklifts, excavators, and similar equipment with design or manufacturing defects</li></ul>

    5 min read
  • Georgia Product Liability Law

    The Three Types of Product Defects in Georgia (Design / Manufacturing / Warning)

    <p>A defective product in Georgia can be defective in one of three ways, and the category determines what the plaintiff must prove. Design defects question the entire product line. Manufacturing defects question a specific unit. Warning defects question the adequacy of instructions or warnings accompanying the product. Each category developed through Georgia case law, and each has its own evidentiary framework.</p> <table> <thead> <tr> <th>Defect type</th> <th>Question</th> <th>Proof framework</th> </tr> </thead> <tbody> <tr> <td>Design</td> <td>Is the entire product line defectively designed?</td> <td><em>Banks</em> risk-utility balancing test</td> </tr> <tr> <td>Manufacturing</td> <td>Did this individual unit deviate from the intended design?</td> <td>Departure from specifications</td> </tr> <tr> <td>Warning</td> <td>Were the warnings or instructions inadequate?</td> <td>Foreseeable-danger duty + warning adequacy</td> </tr> </tbody> </table> <h2>Design defects ask whether the entire product line should never have been made this way</h2> <p>A design defect exists when the product’s intended design is itself unreasonably dangerous, and a feasible safer alternative design existed at the time of manufacture. Every unit produced under that design carries the same defect. The plaintiff is not arguing that something went wrong in making this particular product. The plaintiff is arguing that the product as designed should not have been made.</p> <p>Georgia uses the risk-utility balancing test from <em>Banks v. ICI Americas, Inc.</em>, 264 Ga. 732, 450 S.E.2d 671 (1994), to determine design defect. The jury weighs the risks inherent in the design against the utility derived from the product, considering factors that include:</p> <ul> <li>The usefulness of the product</li> <li>The severity and likelihood of the danger</li> <li>The avoidability of the danger by the user</li> <li>The technology available at the time of manufacture</li> <li>The feasibility of an alternative safer design</li> <li>The cost and practicality of alternative designs</li> <li>The user’s knowledge of the danger</li> </ul> <p>Plaintiffs typically present expert testimony on the feasibility of alternative designs that would have eliminated or reduced the risk while preserving the product’s utility.</p> <h2>Manufacturing defects ask whether this particular unit went wrong</h2> <p>A manufacturing defect exists when an individual product departs from the manufacturer’s intended design due to error during production. Other units produced under the same design may be entirely safe. The defect is specific to the unit that caused the injury.</p> <p>Proof of manufacturing </p>

    5 min read
  • Georgia Product Liability Law

    Product Liability Claims in Georgia: An Overview

    <p>When a defective product causes injury or death in Georgia, the law provides remedies governed primarily by O.C.G.A. § 51-1-11. Product liability sits at the intersection of strict liability under that section, traditional negligence, and warranty law. The framework imposes responsibility on manufacturers for defective products that cause injury when used as foreseeably intended, without requiring the plaintiff to prove the manufacturer was careless.</p> <p>Georgia recognizes three types of product defects, two distinct categories of defendants (manufacturers and product sellers), and a strict ten-year statute of repose that bars most claims after the product’s first sale. Within these structural rules, damages range from compensatory recovery to uncapped punitive damages when the threshold of willful, reckless, or wanton conduct is met.</p> <table> <thead> <tr> <th>Element</th> <th>Governing law</th> </tr> </thead> <tbody> <tr> <td>Strict liability for manufacturers</td> <td>O.C.G.A. § 51-1-11(b)(1)</td> </tr> <tr> <td>Product seller exclusion</td> <td>O.C.G.A. § 51-1-11.1</td> </tr> <tr> <td>Ten-year statute of repose</td> <td>O.C.G.A. § 51-1-11(b)(2)</td> </tr> <tr> <td>Repose exceptions</td> <td>O.C.G.A. § 51-1-11(c)</td> </tr> <tr> <td>Punitive damages, no cap</td> <td>O.C.G.A. § 51-12-5.1(e)(1)</td> </tr> <tr> <td>Risk-utility design defect test</td> <td><em>Banks v. ICI Americas</em>, 264 Ga. 732 (1994)</td> </tr> </tbody> </table> <h2>Strict liability under § 51-1-11 separates product cases from ordinary negligence</h2> <p>Under O.C.G.A. § 51-1-11(b)(1), the manufacturer of personal property sold as new is strictly liable in tort for injury caused by a defective product when the property is used by any natural person as intended. The plaintiff does not need to prove the manufacturer was negligent. The burden is on the plaintiff to show that the product was defective when it left the manufacturer’s control, that the defect proximately caused the injury, and that the product was used in a manner reasonably foreseeable to the manufacturer.</p> <p>This structural difference matters. In a typical negligence case, the plaintiff proves duty, breach, causation, and damages. In a strict liability product case, breach is replaced by proof of a defect; the manufacturer’s level of care is not the question.</p> <h2>Georgia recognizes three categories of product defects</h2> <p>Product defects in Georgia fall into three categories, established through Georgia case law including <em>Banks v. ICI Americas, Inc.</em>, 264 Ga. 732, 450 S.E.2d 671 (1994):</p> <ul> <li><strong>Design defect:</strong> The product’s design is unreasonably dangerous, and a safer alternative </li></ul>

    5 min read
  • Georgia Product Liability Law

    Exceptions to the 10-Year Repose (Long-Latency Disease, Willful Conduct, Continuing Duty)

    <p>The ten-year statute of repose under O.C.G.A. § 51-1-11(b)(2) ends most product liability claims after a decade. But three categories of claims survive past that limit under O.C.G.A. § 51-1-11(c). Each exception responds to a specific category of cases where the repose would produce unjust results.</p> <table> <thead> <tr> <th>Exception (§ 51-1-11(c))</th> <th>What it preserves</th> <th>Typical case examples</th> </tr> </thead> <tbody> <tr> <td>Long-latency disease or birth defect</td> <td>Negligence claims for disease/birth defect manifesting after 10 years</td> <td>Asbestos mesothelioma, certain pharmaceutical injuries, reproductive toxins, prenatal exposure cases</td> </tr> <tr> <td>Willful, reckless, or wanton conduct</td> <td>Negligence claims based on elevated culpability</td> <td>Manufacturer concealment of known risks, continued sale after learning of serious defects, regulatory deception</td> </tr> <tr> <td>Continuing duty to warn</td> <td>Negligence claims based on post-sale warning failures</td> <td>Manufacturer learned of risks after sale and did not warn known purchasers, recall failures</td> </tr> </tbody> </table> <p>All three exceptions preserve negligence claims only. Strict liability claims under § 51-1-11(b)(2) remain barred by the flat ten-year limit.</p> <h2>Three exceptions are codified in § 51-1-11(c)</h2> <p>Under O.C.G.A. § 51-1-11(c), the ten-year repose does not apply to:</p> <ol> <li>Claims arising out of conduct that manifests a willful, reckless, or wanton disregard for life or property</li> <li>Claims involving manufacturing products that cause disease or birth defect</li> <li>The manufacturer’s continuing duty to warn of dangers becoming known after the product is sold</li> </ol> <p>These exceptions function as separate paths to recovery in cases that fall outside the standard ten-year window.</p> <h2>Long-latency disease exception preserves claims where injury manifests slowly</h2> <p>Some injuries do not appear until years or decades after exposure to the causing product. Asbestos-related mesothelioma can develop 20-40 years after exposure. Certain industrial chemicals can cause cancers that emerge decades later. Reproductive toxins can cause birth defects in children of exposed parents.</p> <p>The long-latency exception under § 51-1-11(c) preserves negligence claims for these injuries even when the product was manufactured and sold more than ten years before the disease manifests. The exception is structural: applying a ten-year repose to a 30-year latency disease would extinguish the cause of action before the plaintiff could possibly know they had been injured.</p> <p>The exception is narrower than it might appear. It applies specifically to “disease or </p>

    6 min read
  • Georgia Product Liability Law

    Failure to Warn Claims in Georgia Product Liability

    <p>The defect can be the silence. A product can be defectively designed and properly manufactured but still legally defective because the manufacturer failed to warn users about the risks of its normal use. Failure to warn (sometimes called marketing or packaging defect) is the third category of product liability under Georgia law, and it differs fundamentally from the other two: the question is not whether the product itself is sound, but whether the manufacturer told the user what the user needed to know.</p> <h2>The duty to warn covers known and reasonably foreseeable dangers</h2> <p>Under Georgia law, as recognized in <em>Thornton v. E.I. Du Pont De Nemours & Co.</em>, 22 F.3d 284, 289 (11th Cir. 1994), a manufacturer has a duty to give an adequate warning of known or reasonably foreseeable dangers arising from the use of a product. The duty extends to all persons whom the manufacturer should reasonably foresee may use or be affected by the product.</p> <p>The Georgia Suggested Pattern Jury Instructions, Volume 1, Civil Cases, 5th Edition, No. 62.680, articulate this duty: a manufacturer’s duty to warn may be breached by failing to provide an adequate warning of the product’s potential dangers, or by failing to adequately communicate the warning to the ultimate user.</p> <p>The duty applies to both:</p> <ul> <li>Dangers the manufacturer actually knew about at the time of sale</li> <li>Dangers the manufacturer should have known about through reasonable care, testing, and product monitoring</li> </ul> <h2>Adequacy turns on content, visibility, and communication</h2> <p>A warning can be inadequate in three ways:</p> <table> <thead> <tr> <th>Inadequacy type</th> <th>What fails</th> <th>Common examples</th> </tr> </thead> <tbody> <tr> <td>Content</td> <td>The warning does not address the actual risk</td> <td>Risk omitted entirely; risk minimized through soft language; risk described in terms that don't match the actual hazard</td> </tr> <tr> <td>Visibility</td> <td>The warning is present but cannot be seen</td> <td>Too small, hidden in dense text, placed where users won't look, color that does not stand out</td> </tr> <tr> <td>Communication</td> <td>The warning reaches the wrong audience or in the wrong form</td> <td>Language the user cannot read; technical terms an ordinary user cannot understand; placement that never reaches the actual user (such as in a manual removed before </td></tr></tbody></table>

    5 min read
  • Georgia Product Liability Law

    Comparative Negligence in Georgia Product Liability Cases

    <p>Georgia’s modified comparative negligence rule under O.C.G.A. § 51-12-33 reduces a plaintiff’s recovery by the plaintiff’s percentage of fault and bars recovery entirely when the plaintiff was 50% or more at fault. The rule applies to product liability cases, though its application differs depending on whether the underlying theory is strict liability or negligence and on the specific defenses raised.</p> <table> <thead> <tr> <th></th> <th>Before <em>Johns v. Suzuki</em> (2020)</th> <th>After <em>Johns v. Suzuki</em> (2020)</th> </tr> </thead> <tbody> <tr> <td>Apportionment in strict liability</td> <td>Generally not applied (contributory/comparative negligence not a defense)</td> <td>Applies fully; jury allocates fault to plaintiff</td> </tr> <tr> <td>Plaintiff conduct effect</td> <td>Limited to assumption of risk and product misuse</td> <td>Plaintiff fault apportioned and reduces recovery</td> </tr> <tr> <td>50% bar</td> <td>Did not formally apply to strict liability</td> <td>Applies; plaintiff at 50%+ recovers nothing</td> </tr> <tr> <td>Doctrinal basis</td> <td>Common-law rule rejecting comparative negligence in strict liability</td> <td>§ 51-12-33 displaces the prior common-law rule</td> </tr> </tbody> </table> <h2>Modified comparative negligence is the Georgia default</h2> <p>Under O.C.G.A. § 51-12-33:</p> <ul> <li>The jury allocates fault among all responsible parties as percentages</li> <li>The plaintiff’s recovery is reduced by the plaintiff’s percentage of fault</li> <li>If the plaintiff’s fault is 50% or more, recovery is barred entirely</li> </ul> <p>This is the standard rule that applies to most tort cases in Georgia, including negligence-based product liability claims. The 50% threshold is the dividing line: 49% fault permits recovery (reduced by 49%); 50% fault bars recovery completely.</p> <h2>Johns v. Suzuki settled apportionment for strict products liability claims</h2> <p>Whether comparative negligence applies to strict liability claims under O.C.G.A. § 51-1-11 was settled by the Supreme Court of Georgia in <em>Johns v. Suzuki Motor of America, Inc.</em>, 310 Ga. 159 (2020). The Court held that O.C.G.A. § 51-12-33’s apportionment provisions apply to strict products liability claims, displacing the prior common-law rule that contributory or comparative negligence was not a defense to strict liability. After <em>Johns</em>, juries can apportion fault to plaintiffs in strict products liability cases, and recovery is reduced accordingly.</p> <p>In <em>Johns</em> itself, the jury awarded $12.5 million on the plaintiff’s strict liability and negligence claims arising from a motorcycle brake failure, but apportioned 49% of fault to the plaintiff (who had not changed the brake fluid </p>

    6 min read
  • Georgia Product Liability Law

    Georgia’s Risk-Utility Test for Design Defects (Banks v. ICI Americas)

    <p>The framework Georgia uses to decide design defect claims was established in 1994. <em>Banks v. ICI Americas, Inc.</em>, 264 Ga. 732, 450 S.E.2d 671 (1994), set the risk-utility balancing test that all subsequent Georgia design defect cases apply. The test weighs the risks inherent in a product design against the utility derived from the product, with no single factor controlling.</p> <h2>Banks adopted risk-utility as the controlling Georgia framework</h2> <p>Before <em>Banks</em>, Georgia courts had applied a variety of approaches to design defect claims, including the consumer expectations test from earlier cases such as <em>Center Chemical Co. v. Parzini</em>, 234 Ga. 868 (1975). The Supreme Court of Georgia, after surveying foreign jurisdictions and the Preliminary Draft of the Restatement (Third) of Torts: Products Liability, replaced this with the risk-utility analysis. The Court held that the analysis in <em>Parzini</em> and <em>Mann v. Coast Catamaran Corp.</em>, 254 Ga. 201 (1985), would no longer be applied to design defect cases.</p> <p>The shift was substantive. Under the consumer expectations test, the question was whether the product performed in a way the ordinary consumer would have expected. Under risk-utility, the question is whether the manufacturer should have adopted a reasonably safer design given the costs, benefits, and feasibility at the time of manufacture.</p> <h2>The factors weigh risk against utility, with feasibility of safer alternative design at the center</h2> <p>The <em>Banks</em> opinion set out a non-exhaustive list of factors the jury weighs. The Georgia Suggested Pattern Jury Instructions, Volume 1, Civil Cases, 5th Edition, No. 62.650, incorporates these factors directly:</p> <table> <thead> <tr> <th>Side</th> <th>Factor</th> </tr> </thead> <tbody> <tr> <td>Risk-side</td> <td>Severity of the danger posed by the design</td> </tr> <tr> <td>Risk-side</td> <td>Likelihood of that danger</td> </tr> <tr> <td>Risk-side</td> <td>Avoidability of the danger (user knowledge, publicity, warnings, common knowledge)</td> </tr> <tr> <td>Risk-side</td> <td>User's ability to avoid the danger</td> </tr> <tr> <td>Utility-side</td> <td>Usefulness of the product</td> </tr> <tr> <td>Utility-side</td> <td>Product's appearance and aesthetic attractiveness</td> </tr> <tr> <td>Utility-side</td> <td>Product's utility for multiple uses</td> </tr> <tr> <td>Utility-side</td> <td>Convenience and durability of the product</td> </tr> <tr> <td>Manufacturer control</td> <td>Technology available when the product was manufactured</td> </tr> <tr> <td>Manufacturer control</td> <td>Ability to eliminate the danger without impairing usefulness or making the product too expensive</td> </tr> <tr> <td>Manufacturer control</td> <td>Feasibility of spreading any increased cost through pricing or </td></tr></tbody></table>

    4 min read
  • Georgia Product Liability Law

    Damages Available in Georgia Product Liability Cases

    <p>A successful product liability claim in Georgia can produce three categories of damages: compensatory damages (economic and noneconomic), punitive damages, and (in death cases) wrongful death recovery measured by the full value of the decedent’s life. The damages framework largely parallels other personal injury claims. Several features are specific to product cases.</p> <table> <thead> <tr> <th>Category</th> <th>Statutory cap</th> <th>Allocation</th> <th>Notes</th> </tr> </thead> <tbody> <tr> <td>Economic damages</td> <td>None</td> <td>100% to plaintiff</td> <td>Medical, lost wages, property damage (subject to economic loss rule)</td> </tr> <tr> <td>Noneconomic damages</td> <td>None</td> <td>100% to plaintiff</td> <td>Pain and suffering, mental anguish, loss of enjoyment of life</td> </tr> <tr> <td>Punitive damages (product liability)</td> <td>None, under § 51-12-5.1(e)(1)</td> <td>25% to plaintiff, 75% to State Treasury (less proportional fees and costs)</td> <td>Only one award per defendant per act</td> </tr> <tr> <td>Punitive damages (specific intent)</td> <td>None, under § 51-12-5.1(f)</td> <td>100% to plaintiff</td> <td>Available when defendant acted with specific intent to harm</td> </tr> <tr> <td>Punitive damages (general tort)</td> <td>$250,000, under § 51-12-5.1(g)</td> <td>100% to plaintiff</td> <td>Default cap when no product liability or specific intent</td> </tr> <tr> <td>Wrongful death (full value of life)</td> <td>None</td> <td>100% to wrongful death plaintiff</td> <td>Measured from the decedent's perspective under O.C.G.A. § 51-4-2</td> </tr> </tbody> </table> <h2>Compensatory damages cover the plaintiff’s actual losses</h2> <p>Compensatory damages restore the plaintiff to the position the plaintiff would have been in absent the injury. They divide into economic and noneconomic categories:</p> <p><strong>Economic damages:</strong></p> <ul> <li>Past and future medical expenses</li> <li>Lost wages and lost earning capacity</li> <li>Property damage caused by the defective product (subject to Georgia’s economic loss rule, which generally bars recovery for damage to the product itself absent personal injury or damage to other property)</li> <li>Out-of-pocket expenses caused by the injury</li> <li>Future expenses related to ongoing care, rehabilitation, and adaptive equipment</li> </ul> <p><strong>Noneconomic damages:</strong></p> <ul> <li>Pain and suffering, both past and future</li> <li>Mental anguish and emotional distress</li> <li>Loss of enjoyment of life</li> <li>Permanent impairment or disfigurement</li> <li>Loss of consortium claims by the injured plaintiff’s spouse</li> </ul> <p>There is no statutory cap on noneconomic damages in product liability cases. The Supreme Court of Georgia struck down the medical malpractice noneconomic cap in <em>Atlanta Oculoplastic Surgery v. Nestlehutt</em>, 286 Ga. 731 (2010), and no comparable statutory cap currently applies to product liability noneconomic damages in Georgia.</p> <h2>Punitive </h2>

    6 min read
  • Georgia Product Liability Law

    Georgia’s 10-Year Statute of Repose for Product Liability

    <p>Georgia imposes a hard ten-year limit on most product liability claims. Under O.C.G.A. § 51-1-11(b)(2), no strict liability product action can be commenced more than ten years after the first sale of the product for use or consumption. The repose operates as an absolute bar, not a statute of limitations subject to standard tolling. After the ten-year period, strict liability claims end regardless of when the injury occurred. Negligence claims also end, except in the narrow categories preserved under O.C.G.A. § 51-1-11(c).</p> <table> <thead> <tr> <th></th> <th>Statute of repose (§ 51-1-11(b)(2))</th> <th>Statute of limitations (§ 9-3-33)</th> </tr> </thead> <tbody> <tr> <td>Trigger event</td> <td>First sale of product to intended consumer</td> <td>Date of injury</td> </tr> <tr> <td>Length</td> <td>10 years</td> <td>2 years</td> </tr> <tr> <td>Nature</td> <td>Absolute bar, ends the cause of action</td> <td>Procedural deadline to file suit</td> </tr> <tr> <td>Discovery rule tolling</td> <td>Not available</td> <td>Available in appropriate cases</td> </tr> <tr> <td>Minor tolling (§ 9-3-90)</td> <td>Generally not available</td> <td>Available</td> </tr> <tr> <td>Exceptions</td> <td>§ 51-1-11(c) (3 categories, negligence only)</td> <td>Standard tolling rules</td> </tr> </tbody> </table> <h2>Repose runs from the first sale, not the manufacture</h2> <p>The Supreme Court of Georgia resolved a long-running question about the trigger date in <em>Campbell v. Altec Industries, Inc.</em>, 288 Ga. 535 (2011). In response to a certified question from the Eleventh Circuit, the Court held that the statute of repose begins to run when the finished product is sold as new to the intended consumer who is to receive the product.</p> <p>This holding settled several alternative readings:</p> <ul> <li>Repose does not run from when a component is assembled or tested</li> <li>Repose does not run from when the finished product is manufactured</li> <li>Repose does not run from intermediate sales in the distribution chain</li> <li>Repose runs from the first sale to the intended end user</li> </ul> <p>A truck sold new in 2014 remains within the repose period until 2024, regardless of when its component parts were manufactured or when it changed hands among subsequent owners.</p> <h2>The repose is absolute, not a statute of limitations</h2> <p>A statute of limitations defines how long after an injury a plaintiff has to file suit. A statute of repose defines how long after a triggering event (here, first sale) the cause of action can exist at all. The repose </p>

    5 min read
  • Georgia Product Liability Law

    Punitive Damages in Georgia Product Liability (No Cap + 75% State Share)

    <p>Georgia’s punitive damages framework treats product liability differently from other tort cases. Under O.C.G.A. § 51-12-5.1(e)(1), there is no $250,000 cap on punitive damages in product liability cases. The general cap in § 51-12-5.1(g), affirmed as constitutional by the Supreme Court of Georgia in <em>Taylor v. The Devereux Foundation</em> (2023), does not apply when the cause of action arises from product liability. But the absence of a cap comes with a structural cost: 75% of any uncapped punitive award goes to the State Treasury under § 51-12-5.1(e)(2).</p> <table> <thead> <tr> <th>Statute provision</th> <th>Applies to</th> <th>Cap</th> <th>Plaintiff share</th> </tr> </thead> <tbody> <tr> <td>§ 51-12-5.1(e)(1)</td> <td>Product liability cases</td> <td>No cap</td> <td>25% (75% to State Treasury under (e)(2))</td> </tr> <tr> <td>§ 51-12-5.1(f)</td> <td>Specific intent to cause harm</td> <td>No cap</td> <td>100% to plaintiff</td> </tr> <tr> <td>§ 51-12-5.1(f)</td> <td>Impaired conduct (alcohol/drugs)</td> <td>No cap</td> <td>100% to plaintiff</td> </tr> <tr> <td>§ 51-12-5.1(g)</td> <td>All other tort cases</td> <td>$250,000</td> <td>100% to plaintiff</td> </tr> </tbody> </table> <p>In <em>Taylor v. The Devereux Foundation</em> (March 2023), the Supreme Court of Georgia affirmed the constitutionality of the $250,000 cap under (g) against jury-trial and due-process challenges.</p> <h2>The product liability exception removes the general cap</h2> <p>Most tort cases in Georgia face a $250,000 cap on punitive damages under O.C.G.A. § 51-12-5.1(g). The cap survives constitutional challenges, including the <em>Taylor v. The Devereux Foundation</em> decision in 2023 in which the Supreme Court of Georgia affirmed the cap’s constitutionality for tort cases not arising from product liability, specific intent to harm, or impaired conduct.</p> <p>Three exceptions remove the cap:</p> <ul> <li><strong>Product liability cases</strong> (§ 51-12-5.1(e)(1)): no limit on punitive damages</li> <li><strong>Specific intent to cause harm</strong> (§ 51-12-5.1(f)): no limit when defendant acted with specific intent</li> <li><strong>Impaired conduct</strong> (§ 51-12-5.1(f)): no limit when defendant was substantially impaired by alcohol or drugs</li> </ul> <p>When the case arises from product liability, the cap removal is automatic; no separate finding of specific intent or impairment is required.</p> <h2>The clear and convincing evidence threshold still applies</h2> <p>Cap removal does not lower the threshold for punitive damages. Under O.C.G.A. § 51-12-5.1, punitive damages still require clear and convincing evidence of:</p> <ul> <li>Willful misconduct</li> <li>Malice</li> <li>Fraud</li> <li>Wantonness</li> <li>Oppression</li> <li>That entire want of care which raises the presumption of conscious indifference to consequences</li></ul>

    6 min read
  • Georgia Product Liability Law

    Strict Liability vs. Negligence in Georgia Product Liability

    <p>A plaintiff injured by a defective product in Georgia has two distinct theories available, and the choice between them shapes what must be proved at trial. Strict liability under O.C.G.A. § 51-1-11 removes the question of the manufacturer’s care from the case. Negligence keeps that question central. Both theories can be pleaded in the same complaint, but they impose different burdens on the plaintiff and offer different defenses to the manufacturer.</p> <table> <thead> <tr> <th></th> <th>Strict Liability (§ 51-1-11(b)(1))</th> <th>Negligence</th> </tr> </thead> <tbody> <tr> <td>Required proof</td> <td>Defective product + causation</td> <td>Duty + breach + causation + damages</td> </tr> <tr> <td>Manufacturer's care</td> <td>Not relevant</td> <td>Central question</td> </tr> <tr> <td>Available defendants</td> <td>Manufacturers only (§ 51-1-11.1 bars sellers)</td> <td>Manufacturers, sellers, designers, and other distribution-chain entities</td> </tr> <tr> <td>Statute of repose application</td> <td>Yes, 10 years from first sale</td> <td>Yes, under § 51-1-11(c) (with exceptions)</td> </tr> <tr> <td>Punitive damages cap</td> <td>None, under § 51-12-5.1(e)(1)</td> <td>None, under § 51-12-5.1(e)(1), if product liability</td> </tr> </tbody> </table> <h2>Strict liability turns on the product, not the manufacturer’s conduct</h2> <p>Under O.C.G.A. § 51-1-11(b)(1), strict liability requires the plaintiff to prove that the manufacturer placed a defective product in the stream of commerce, that the product was used in a manner the manufacturer could reasonably foresee, and that the defect proximately caused the injury. The manufacturer’s level of care is not an element. A manufacturer can be held strictly liable even when it exercised reasonable care in design and production, provided the resulting product was defective.</p> <p>Georgia adopted this strict liability framework through § 51-1-11, and the Supreme Court of Georgia has interpreted it consistently as imposing tort liability under a breach-of-contract standard rather than a negligence standard. <em>Higginbotham v. Ford Motor Co.</em>, 540 F.2d 762 (5th Cir. 1976), and subsequent decisions confirm that fitness, not fault, drives liability under § 51-1-11(b)(1).</p> <h2>Negligence keeps the manufacturer’s care as the central question</h2> <p>A negligence claim against a manufacturer requires proof that the manufacturer breached a duty of care owed to the plaintiff and that the breach caused the injury. The plaintiff must identify specifically what the manufacturer did or failed to do that fell below the standard of reasonable care.</p> <p>Negligence theories in product cases commonly include:</p> <ul> <li>Negligent design (failing </li></ul>

    5 min read
  • Georgia Product Liability Law

    Manufacturing Defects Under Georgia Law

    <p>A manufacturing defect exists when a single product unit departs from the manufacturer’s intended design due to error during production. Unlike design defects, which question the entire product line, manufacturing defects question only the specific unit that caused the injury. Other products produced under the same design may be entirely safe.</p> <table> <thead> <tr> <th></th> <th>Design defect</th> <th>Manufacturing defect</th> </tr> </thead> <tbody> <tr> <td>Scope</td> <td>Entire product line</td> <td>Specific unit only</td> </tr> <tr> <td>Question</td> <td>Is the design unreasonable?</td> <td>Did this unit deviate from spec?</td> </tr> <tr> <td>Proof framework</td> <td><em>Banks</em> risk-utility test</td> <td>Departure from manufacturer's specifications</td> </tr> <tr> <td>Causation</td> <td>Design choice → injury</td> <td>This specific unit → injury</td> </tr> <tr> <td>Other units</td> <td>All carry the defect</td> <td>May be entirely safe</td> </tr> <tr> <td>Typical experts</td> <td>Engineering, alternative design</td> <td>Quality control, materials, production</td> </tr> </tbody> </table> <h2>The legal question is narrower than design defect</h2> <p>To prove a manufacturing defect under O.C.G.A. § 51-1-11(b)(1), the plaintiff must show:</p> <ul> <li>The product was defective when it left the manufacturer’s control</li> <li>The defect was a departure from the manufacturer’s own design or specifications</li> <li>The defect proximately caused the injury</li> <li>The product was used as the manufacturer could reasonably have foreseen</li> </ul> <p>The plaintiff does not need to prove that the design was unreasonable. The plaintiff needs to prove that this particular product was not built according to that design.</p> <h2>Proof typically rests on physical comparison</h2> <p>Manufacturing defect proof in Georgia practice typically involves:</p> <ul> <li>The injuring product itself preserved as evidence</li> <li>The manufacturer’s design specifications, blueprints, or production standards</li> <li>Other units from the same production run for comparison</li> <li>Expert testimony identifying how the injuring unit deviated from the standard</li> </ul> <p>When the manufacturer’s specifications are available, the comparison can be direct: this unit has dimensions, materials, or assembly that do not match what the manufacturer intended to produce.</p> <p>When specifications are not directly available, plaintiffs may need to rely on expert reconstruction of what the manufacturer should have produced, supported by industry standards, similar products, or earlier units from the same line.</p> <h2>Some manufacturing defects are obvious; others require destructive testing</h2> <p>Manufacturing defects vary in their visibility:</p> <ul> <li><strong>Obvious defects:</strong> A missing safety component, a clearly cracked structural part, an incorrectly installed assembly. These can sometimes be identified visually.</li> <li><strong>Internal defects:</strong> Improper welds, </li></ul>

    5 min read
  • Georgia Product Liability Law

    The Learned Intermediary Doctrine in Georgia

    <p>The learned intermediary doctrine modifies the duty to warn in prescription drug and medical device cases. Under the doctrine, a manufacturer’s duty to warn about the risks of a prescription drug or medical device is satisfied by adequately warning the prescribing physician, not by warning the patient directly. The doctor, as a learned intermediary with specialized knowledge, is responsible for communicating risks to the patient.</p> <h2>The doctrine reflects the practical structure of prescription medicine</h2> <p>A pharmaceutical manufacturer cannot directly counsel every patient about every drug. Patients receive prescription medications through a structured pathway: physician selection, prescription, pharmacist dispensing, patient use. The physician’s role is central. The doctor knows the patient’s medical history, weighs the drug’s risks against benefits for that specific patient, and has direct contact with the patient to communicate risks.</p> <p>The learned intermediary doctrine accepts this structure. It does not eliminate the manufacturer’s duty to warn; it locates the duty at the physician level rather than the patient level. The manufacturer must provide adequate warnings to the medical community through product labeling, package inserts, prescribing information, and direct communications with physicians. When these warnings are adequate, the manufacturer has discharged its failure-to-warn obligation.</p> <h2>Adequate physician-level warning is the defense threshold</h2> <p>A pharmaceutical manufacturer raising the learned intermediary doctrine as a defense must establish that its warnings to prescribing physicians were adequate to inform the medical community of the relevant risks. This typically involves:</p> <ul> <li>FDA-approved product labeling that addresses the risk</li> <li>Package inserts and prescribing information distributed to physicians</li> <li>Dear Doctor letters or similar communications when new risks emerge</li> <li>Continuing medical education and detailing efforts</li> </ul> <p>If the manufacturer’s warnings to physicians were inadequate (the warning omitted the risk that caused the injury, minimized it, or failed to communicate it effectively), the doctrine does not protect the manufacturer. The plaintiff can still proceed with a failure-to-warn claim against the manufacturer based on the inadequate physician-level warnings.</p> <h2>The doctrine applies most clearly to prescription drugs and medical devices</h2> <p>The learned intermediary doctrine in Georgia applies most squarely to:</p> <ul> <li>Prescription pharmaceuticals</li> <li>Prescription medical devices (devices that require a prescription or physician-directed use)</li></ul>

    4 min read
  • Georgia Product Liability Law

    Manufacturer vs. Product Seller Under O.C.G.A. § 51-1-11.1

    <p>Georgia separates entities in the chain of commerce into two categories for product liability purposes. Manufacturers face strict liability under O.C.G.A. § 51-1-11(b)(1). Product sellers do not. The distinction, codified in O.C.G.A. § 51-1-11.1 (enacted in 1987 and applicable to causes of action accruing on or after July 1, 1987), shapes which defendants can be named under which theories.</p> <table> <thead> <tr> <th>Category</th> <th>Strict liability under § 51-1-11(b)(1)?</th> <th>Negligence claims?</th> </tr> </thead> <tbody> <tr> <td>Manufacturer</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Product seller (§ 51-1-11.1)</td> <td>No</td> <td>Yes</td> </tr> </tbody> </table> <h2>The statute defines “product seller” broadly</h2> <p>Under O.C.G.A. § 51-1-11.1(a), a product seller is a person who, in the course of a business conducted for that purpose, engages in any of the following activities:</p> <ul> <li>Leases or sells and distributes products</li> <li>Installs products</li> <li>Prepares, blends, packages, or labels products</li> <li>Markets products</li> <li>Assembles products pursuant to a manufacturer’s plan, intention, design, specifications, or formulation</li> <li>Repairs or maintains products</li> <li>Otherwise places products in the stream of commerce</li> </ul> <p>The definition excludes entities that, because of their activities, fall within the broader definition of “manufacturer.” A manufacturer that also performs seller functions remains a manufacturer.</p> <h2>Strict liability is confined to actual manufacturers</h2> <p>Under O.C.G.A. § 51-1-11.1(b), a product seller is not a manufacturer for purposes of strict liability under § 51-1-11, and is not liable as such. Georgia federal courts have applied this strictly. In <em>Freeman v. United Cities Propane Gas of Ga., Inc.</em>, 807 F. Supp. 1533 (M.D. Ga. 1992), a propane gas retailer and distributor were held not to be manufacturers. The Georgia Court of Appeals confirmed the seller/manufacturer line in <em>Ream Tool Co. v. Newton</em>, 209 Ga. App. 226, 433 S.E.2d 67 (1993), holding that a mere product seller is not a manufacturer and is not liable as a manufacturer on grounds of strict liability.</p> <p>The Supreme Court of Georgia further refined the line in <em>Farmex Inc. v. Wainwright</em>, 269 Ga. 548, 501 S.E.2d 802 (1998), holding that a corporation that purchased the assets of a manufacturer and sold (but did not itself manufacture) a product of the predecessor’s design was a product seller, not a manufacturer subject to strict liability for product </p>

    5 min read
  • Georgia Product Liability Law

    Pharmaceutical Product Liability in Georgia

    <p>Pharmaceutical product liability cases combine Georgia state law with federal FDA regulation, the learned intermediary doctrine, and a complex federal preemption framework that differs sharply between brand-name and generic drug manufacturers. The viability of state law claims often depends on which version of the drug the plaintiff took and what theory is pleaded.</p> <h2>Brand-name and generic drugs face different preemption analyses</h2> <p>The federal preemption landscape in pharmaceutical cases divides sharply:</p> <table> <thead> <tr> <th>Drug type</th> <th>Failure-to-warn preemption</th> </tr> </thead> <tbody> <tr> <td>Brand-name drug</td> <td>Generally not preempted (<em>Wyeth v. Levine</em>, 2009)</td> </tr> <tr> <td>Generic drug</td> <td>Generally preempted (<em>PLIVA, Inc. v. Mensing</em>, 2011)</td> </tr> </tbody> </table> <p>This distinction has practical consequences. Patients injured by brand-name drugs have viable state law failure-to-warn theories. Patients injured by generic drugs face significant preemption barriers and may have no viable state law failure-to-warn remedy against the generic manufacturer.</p> <h2>Wyeth preserves state law claims against brand-name manufacturers</h2> <p>In <em>Wyeth v. Levine</em>, 555 U.S. 555 (2009), the U.S. Supreme Court held that state law failure-to-warn claims against brand-name drug manufacturers are not generally preempted by federal labeling requirements. The reasoning: brand-name manufacturers can unilaterally strengthen their labeling under the FDA’s Changes Being Effected (CBE) regulations without prior FDA approval. State law claims requiring stronger warnings are therefore not made impossible by federal law.</p> <p><em>Wyeth</em> preserves the standard state law failure-to-warn analysis against brand-name manufacturers in most circumstances. The narrow exception is when the FDA has specifically rejected the warning the state law would require, but the manufacturer bears a heavy burden to establish this exception.</p> <h2>PLIVA largely forecloses state law failure-to-warn claims against generic manufacturers</h2> <p>In <em>PLIVA, Inc. v. Mensing</em>, 564 U.S. 604 (2011), the U.S. Supreme Court held that state law failure-to-warn claims against generic drug manufacturers are preempted by federal law. Under the Hatch-Waxman Act, generic manufacturers are required to use the same labeling as the brand-name reference drug. They cannot unilaterally change the labeling to add warnings.</p> <p>Because federal law made it impossible for a generic manufacturer to add warnings the state law claim would require, state law failure-to-warn claims against generic manufacturers are preempted by impossibility preemption.</p> <p>The decision has broad consequences:</p> <ul> <li>Patients who </li></ul>

    5 min read
  • Georgia Product Liability Law

    Consumer Product Liability in Georgia (Appliances, Electronics)

    <p>Consumer product injuries (burns from appliances, fires from electronics, injuries from household tools, harm from children’s products) produce product liability claims under Georgia’s standard framework. The cases share certain features that distinguish them from industrial or medical product liability: the Consumer Product Safety Commission (CPSC) regulates many of these products, recall histories play a central role, and the products are often used in residential settings by ordinary consumers without specialized training.</p> <h2>CPSC regulation and recalls provide important evidence</h2> <p>The Consumer Product Safety Commission (CPSC) regulates consumer products under the Consumer Product Safety Act. CPSC activities generate evidence that plays a central role in product liability cases:</p> <ul> <li>CPSC recall notices establish manufacturer awareness of defects</li> <li>CPSC NEISS injury data documents injury patterns</li> <li>Civil penalty actions by CPSC against manufacturers reveal misconduct</li> <li>Section 15(b) reports filed by manufacturers (notifying CPSC of substantial product hazards) become discoverable</li> <li>CPSC investigation files can reveal internal manufacturer documents</li> </ul> <p>Plaintiffs in consumer product cases obtain CPSC materials through FOIA requests, civil discovery, or both. The materials frequently establish that the manufacturer knew about defects through consumer complaints, injury reports, or internal testing before the plaintiff was injured.</p> <h2>Consumer product cases fall into recurring defect categories</h2> <table> <thead> <tr> <th>Category</th> <th>Common risk type</th> <th>Examples</th> </tr> </thead> <tbody> <tr> <td>Appliances</td> <td>Fire, scald, mechanical injury</td> <td>Stoves, refrigerators, washing machines, dryers</td> </tr> <tr> <td>Small kitchen appliances</td> <td>Burns</td> <td>Pressure cookers, slow-cookers, multi-cookers, coffee makers</td> </tr> <tr> <td>Electronics</td> <td>Battery fire, electrical shock</td> <td>Lithium-ion battery products, chargers, devices with electrical hazards</td> </tr> <tr> <td>Children's products</td> <td>Injury, suffocation, death</td> <td>Toys, cribs, strollers, car seats, high chairs</td> </tr> <tr> <td>Furniture</td> <td>Tip-over crush injury</td> <td>Dressers, TV stands</td> </tr> <tr> <td>Recreational products</td> <td>Crash, fire</td> <td>ATVs, dirt bikes, recreational watercraft, hoverboards</td> </tr> <tr> <td>Power tools</td> <td>Laceration, amputation, electric shock</td> <td>Consumer-grade saws, drills, mowers</td> </tr> <tr> <td>Cleaning products and chemicals</td> <td>Toxicity, burns</td> <td>Products with hazardous foreseeable-use exposure</td> </tr> <tr> <td>Personal care products</td> <td>Burns</td> <td>Hair dryers, irons, curling irons</td> </tr> </tbody> </table> <p>Each defect category has developed its own line of case law and recall history.</p> <h2>Children’s products receive elevated regulatory and legal scrutiny</h2> <p>Products designed for or used by children receive particular regulatory attention. CPSC enforces specific children’s product standards, including:</p> <ul> <li>The Consumer Product Safety Improvement Act of 2008 (CPSIA), which imposed stricter safety standards on </li></ul>

    5 min read
  • Georgia Product Liability Law

    Defective Vehicle Product Liability in Georgia

    <p>Vehicle defect cases combine Georgia’s strict liability framework under O.C.G.A. § 51-1-11 with federal motor vehicle safety regulations and crashworthiness doctrine. The cases often involve multiple defendants (vehicle manufacturer, component manufacturers, dealers), multiple defect theories (design, manufacturing, warning), and significant interaction with federal preemption.</p> <h2>Vehicle defects commonly fall in several recurring categories</h2> <p>Vehicle product liability cases in Georgia typically involve one or more of the following defect categories:</p> <ul> <li><strong>Crashworthiness failures:</strong> The vehicle structure did not protect occupants in foreseeable crashes (roof crush in rollovers, fuel system fires in collisions, seat belt failures)</li> <li><strong>Restraint system defects:</strong> Airbags that did not deploy when they should have, deployed when they should not have, or deployed with excessive force</li> <li><strong>Brake system failures:</strong> Brake design or component defects causing inability to stop</li> <li><strong>Steering and suspension defects:</strong> Failures causing loss of control</li> <li><strong>Tire defects:</strong> Tread separation, sidewall failures, or other tire-related crashes</li> <li><strong>Electronic system failures:</strong> Defects in vehicle electronics affecting safety-critical functions</li> <li><strong>Fuel system defects:</strong> Designs prone to fire in collisions</li> <li><strong>Tip-over and rollover propensity:</strong> SUV and truck designs with elevated centers of gravity</li> </ul> <p>The technical proof framework differs by category, and engineering experts address the specific failure mechanism in each case.</p> <h2>Crashworthiness doctrine applies to enhanced injury cases</h2> <p>Georgia recognizes crashworthiness (also called “second collision” or “enhanced injury”) as a viable product liability theory. The doctrine holds that vehicle manufacturers have a duty to design vehicles that minimize injuries in foreseeable crashes, even when the manufacturer did not cause the crash itself.</p> <p>The doctrine produces two distinct phases of analysis:</p> <ol> <li><strong>The first collision:</strong> The cause of the crash itself (which may involve another driver, road conditions, or other factors)</li> <li><strong>The second collision:</strong> The plaintiff’s interaction with the vehicle interior, which the manufacturer should have designed to minimize injury</li> </ol> <p>Crashworthiness claims focus on the second collision. They do not require proof that the manufacturer caused the crash. They require proof that the vehicle’s design exacerbated injuries that would have been less severe in a properly designed vehicle.</p> <h2>Federal regulation interacts with Georgia state law claims</h2> <p>The National Highway Traffic Safety Administration (NHTSA) regulates motor vehicle safety </p>

    5 min read
  • Georgia Product Liability Law

    Federal Preemption Defenses (Medical Devices, Generic Drugs)

    <p>Some product liability claims under Georgia state law are barred by federal preemption. When federal law occupies the field, conflicts with state law, or creates parallel regulatory requirements, state law claims that would impose duties beyond or in addition to the federal scheme can be preempted. The doctrine operates most forcefully in medical device cases involving devices that received FDA premarket approval and in pharmaceutical cases involving generic drugs.</p> <table> <thead> <tr> <th>Preemption category</th> <th>Source</th> <th>Key Supreme Court case</th> </tr> </thead> <tbody> <tr> <td>Medical device (FDA premarket approval)</td> <td>Medical Device Amendments § 360k</td> <td><em>Riegel v. Medtronic</em>, 552 U.S. 312 (2008)</td> </tr> <tr> <td>Generic drug failure to warn</td> <td>Hatch-Waxman + federal labeling requirements</td> <td><em>PLIVA, Inc. v. Mensing</em>, 564 U.S. 604 (2011)</td> </tr> <tr> <td>Brand-name drug</td> <td>Federal labeling vs. state common law</td> <td><em>Wyeth v. Levine</em>, 555 U.S. 555 (2009)</td> </tr> </tbody> </table> <h2>Medical device preemption requires premarket approval and excess state duties</h2> <p>In <em>Riegel v. Medtronic, Inc.</em>, 552 U.S. 312 (2008), the U.S. Supreme Court held that the Medical Device Amendments expressly preempt state common law claims that would impose requirements different from or in addition to federal requirements applicable to medical devices that received FDA premarket approval (PMA).</p> <p>The doctrine has two essential components:</p> <ol> <li><strong>The device must have received premarket approval (PMA).</strong> Devices cleared through the less rigorous 510(k) process are generally not subject to <em>Riegel</em> preemption.</li> <li><strong>The state claim must impose duties different from or in addition to federal requirements.</strong> Claims that parallel federal requirements (state law claims based on the manufacturer’s failure to comply with FDA-approved specifications) remain available.</li> </ol> <p>Plaintiffs can pursue “parallel claims” where state law duties match federal requirements, such as a state law claim that the manufacturer failed to manufacture the device in accordance with the FDA-approved specifications. These claims are not preempted because they enforce, rather than supplement, federal requirements.</p> <h2>The Riegel analysis turns on specific federal requirements</h2> <p>Whether a state claim is preempted under <em>Riegel</em> depends on the specific federal requirements applicable to the device. Courts examine:</p> <ul> <li>The FDA labeling approved for the device</li> <li>The manufacturing specifications approved in the PMA</li> <li>The conditions imposed by FDA on the device’s approval</li> <li>Any post-approval changes the FDA required</li> </ul> <p>A </p>

    5 min read